Compare FSLY & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSLY | TLX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.6B |
| IPO Year | 2019 | N/A |
| Metric | FSLY | TLX |
|---|---|---|
| Price | $17.69 | $10.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $18.00 | ★ $21.13 |
| AVG Volume (30 Days) | ★ 6.5M | 192.7K |
| Earning Date | 05-06-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $624,018,000.00 | N/A |
| Revenue This Year | $16.39 | N/A |
| Revenue Next Year | $10.73 | N/A |
| P/E Ratio | ★ N/A | $150.33 |
| Revenue Growth | ★ 14.78 | N/A |
| 52 Week Low | $6.29 | $6.28 |
| 52 Week High | $34.82 | $16.95 |
| Indicator | FSLY | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 57.09 |
| Support Level | $16.06 | $10.06 |
| Resistance Level | $20.27 | $10.33 |
| Average True Range (ATR) | 1.64 | 0.27 |
| MACD | 0.10 | 0.09 |
| Stochastic Oscillator | 18.24 | 95.24 |
Fastly Inc is a cloud computing company that provides an edge cloud platform designed to deliver, secure, and optimize digital experiences over the internet. The company operates a unified platform that combines content delivery, edge computing, and security capabilities. Its services include content delivery networks, web and API protection, distributed denial of service mitigation, and real-time data processing at the edge. Its platform enables customers to improve the performance, scalability, and security of applications and digital content, and also supports cloud-native architectures, AI-driven workloads, and programmable edge computing solutions.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.